Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759564 | 0.84 | SCN7A (0.56) | DRD2DRD4CHRM3 | |
| SCHEMBL19430661 | 0.83 | KDM4E (0.47) | — | |
| SCHEMBL20910929 | 0.79 | SCN7A (0.54) | DRD2DRD4 | |
| SCHEMBL16758978 | 0.78 | SCN7A (0.56) | DRD2DRD4CHRM3ACHECHRM2 | |
| SCHEMBL16759678 | 0.77 | SCN7A (0.70) | DRD2DRD4 | |
| SCHEMBL18263311 | 0.76 | MGLL (0.44) | — | |
| SCHEMBL20843153 | 0.74 | KDM1A (0.53) | DRD2DRD4ACHEBCHE | |
| SCHEMBL12814152 | 0.74 | KDM1A (0.53) | DRD2DRD4 | |
| SCHEMBL18243724 | 0.73 | MGLL (0.47) | — | |
| SCHEMBL19764432 | 0.73 | KDM1A (0.51) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | DRD2 1228/4885DRD4 738/4885MCHR1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.